Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;22(12):2640-2645.
doi: 10.1093/annonc/mdr020. Epub 2011 Mar 17.

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients

X-X He  1 , S M Tu  2 , M-H Lee  3 , S-C J Yeung  4
Affiliations

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients

X-X He et al. Ann Oncol. 2011 Dec.

Abstract

Background: The association between antidiabetic medications and the prognosis of human prostate cancer has not been explored. This study examined the impact of these drugs on the outcomes of diabetic patients with prostate cancer to provide a basis for diabetes management strategy in these patients.

Patients and methods: Records of consecutive prostate cancer patients with coexisting diabetes mellitus type 2 who were treated at the study institution between 15 July 1999 and 31 December 2008 were reviewed. The survival, cancer pathological grade, stage at the time of diagnosis, and antidiabetic pharmacotherapy of the patients were analyzed.

Results: A total of 233 consecutive cases were analyzed. In Kaplan-Meier analysis, thiazolidinedione (log-rank, P = 0.005) and metformin (log-rank, P = 0.035) usage were significant predictors of improved overall survival, while insulin and insulin secretagogue usage were not significant predictors. Multivariate Cox regression analysis showed that thiazolidinedione {hazard ratio [HR] = 0.454 [95% confidence interval (CI) 0.213-0.965], P = 0.040} and metformin [HR = 0.550 (95% CI 0.315-0.960), P = 0.035] usage remained as significant predictors of favorable survival after controlling for variables including age, race, Gleason grade, and stage.

Conclusions: Thiazolidinediones and metformin appear to be associated with improved overall survival of diabetic prostate cancer patients. The choice of antidiabetic pharmacotherapy may influence overall survival of these patients.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Thiazolidinediones and metformin are associated with improved survival of diabetic prostate cancer patients. Kaplan–Meier survival curves comparing ever-users and never-users are shown for thiazolidinediones (A), metformin (B), thiazolidinediones and/or metformin (C), insulins and insulin analogues (D), insulin secretagogues (E), and insulins or analogues and/or insulin secretagogues (F). The P values of the log-rank tests are as labeled.
See this image and copyright information in PMC

References

    1. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer. 2001;84:417–422. - PMC - PubMed
    1. Verlato G, Zoppini G, Bonora E, Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care. 2003;26:1047–1051. - PubMed
    1. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005;2:48–53. - PubMed
    1. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160–1167. - PubMed
    1. Giovannucci E, Rimm EB, Stampfer MJ, et al. Diabetes mellitus and risk of prostate cancer (United States) Cancer Causes Control. 1998;9:3–9. - PubMed

Publication types

MeSH terms